serpin family I member 2Genealiases: MEPI · PANCPIN · PI14 · TSA2004
Q-omics provides the consensus-scored SERPINI2 profile across patient tissues and cancer cell-line models. SERPINI2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, SERPINI2 is differentially expressed in 9, with the highest sampling consensus in LUAD. Additionally, SERPINI2 RNA expression shows 14,256 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KICH, LUAD, and PDAC as cancer lineages where SERPINI2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SERPINI2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SERPINI2 survival associations across molecular data types. SERPINI2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SERPINI2 RNA expression–survival associations across cancer types. High SERPINI2 expression shows unfavorable associations in KICH, LIHC, KIRC and THCA, but favorable associations in BRCA and ACC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for SERPINI2 RNA expression.
This table summarizes SERPINI2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 4. The strongest signals are observed in LUAD for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for SERPINI2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SERPINI2 shows lower tumor expression in LUAD, HNSC, KICH, THCA, LUSC and BLCA. The LUAD box plot shows higher SERPINI2 RNA expression in normal versus tumor tissue (log2 FC = −0.665, t-test p < 0.001).
This table shows molecular features associated with SERPINI2 in patient tissues and cancer cell lines. In patient samples, SERPINI2 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, SERPINI2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
